Slide1.jpg
 

A smart, wearable solution that empowers physicians and DVT patients by providing on-the-go monitoring and as-needed treatment.

Incubated by IntuitiveX


SUMMARY

Deep Vein Thrombosis (DVT) are blood clots that most commonly develop in the lower extremities and are considered to be serious medical conditions. They can develop into an even more serious condition called pulmonary embolism (PE) which are blood clots in the vascular system within the lungs that can prove to be fatal. Patients who are hospitalized are at an increased risk for both DVT and PE (collectively known as Venous Thrombo Embolism, or VTE), which are considered to be major health concerns.

DVT and PE result in over 100,000 annual deaths, twice that of breast cancer. Here is an opportunity to drive market awareness of DVT and address risk factors.

Our product is designed to address the issue of DVTs embedded with the following features: 1) a wearable compression sock or sleeve that allows the wearer to remain mobile, 2) an accelerometer to measure the mobility/immobility of the wearer, 3) an alert system (audible beep and/or vibration) to notify the wearer, caretaker, and/or healthcare personnel of the wearer’s relative immobility, 4) the ability of the wearable device to communicate the information regarding the wearer’s activity with another device (e.g., computer, smart phone, etc.) via Bluetooth and/or the cloud.

 

THE PROBLEM

Deep Vein Thrombosis (DVT) and Pulmonary Embolisms (PE) result in over 100,000 annual deaths, twice that of breast cancer. Here is an opportunity to drive market awareness of DVT and address risk factors.

 

OUR SOLUTION

Circulex is a simple solution designed to address DVT risk factors via a smart compression sleeve utilizing neuromuscular electrical stimulation and cloud-based software. A user’s mobility is tracked and notifications are provided when detectable concerns arise. This smart device reduces DVT risk factors while providing both users and healthcare professionals with comprehensive user data that might not otherwise be attainable.

 

THE MARKET

The total available market, inclusive of DVT at risk cases, is 445M. Circulex will target the travel segment of 108M in year 1, adding the hospitalization segment of 35M in year 2, and the related segments of 188M in year 3. The segmented available market for Circulex in years 1-5 is 271M, which at $99 per unit, totals available revenue of $27B in first 5 years. Based on estimated and scalable market penetration of .25% - 1.0% during these initial years, revenue is projected to beat $223M by year 2021.

 

INVESTMENT

Raising $1.5M for:

  • Product manufacturing

  • Pilot launch to retail market

  • FDA testing & approval

 

THE TEAM

CEO: Joseph Ross

CMO: Jeffrey Roh, MD, MBA

Product: Jason Duncan, MBA